Yesterday, April 5, 2016, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $11.52 to $16,431,746.56.

Highlighted Stocks Traded by Insiders:

Tanger Factory Outlet Centers (SKT) - FREE Research Report

McDonough Thomas E., who is EVP, Chief Operating Officer at Tanger Factory Outlet Centers, sold 11,546 shares at $36.14 on April 5, 2016. Following this transaction, the EVP, Chief Operating Officer owned 171,396 shares meaning that the stake was reduced by 6.31% with the 11,546-share transaction.

The shares most recently traded at $36.06, down $0.08, or 0.22% since the insider transaction. Historical insider transactions for Tanger Factory Outlet Centers go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 5,392
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 34,480
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 78,846

The average volume for Tanger Factory Outlet Centers has been 740,700 shares per day over the past 30 days. Tanger Factory Outlet Centers has a market cap of $3.5 billion and is part of the financial sector and real estate industry. Shares are up 10.64% year-to-date as of the close of trading on Tuesday.

Tanger Factory Outlet Centers, Inc. is a real estate investment trust. The firm invests in the real estate markets in United States. It focuses on developing, acquiring, owning, operating, and managing outlet shopping centers. Tanger Factory Outlet Centers, Inc. The stock currently has a dividend yield of 3.13%. The company has a P/E ratio of 16.5. Currently, there is 1 analyst who rates Tanger Factory Outlet Centers a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKT - FREE

TheStreet Quant Ratings

rates Tanger Factory Outlet Centers as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full

Tanger Factory Outlet Centers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Foundation Medicine (FMI) - FREE Research Report

Miller Vincent A., who is Chief Medical Officer at Foundation Medicine, sold 356 shares at $18.08 on April 5, 2016. Following this transaction, the Chief Medical Officer owned 78,482 shares meaning that the stake was reduced by 0.45% with the 356-share transaction.

Kafka Steven J., who is President & COO at Foundation Medicine, sold 124 shares at $18.08 on April 5, 2016. Following this transaction, the President & COO owned 41,226 shares meaning that the stake was reduced by 0.3% with the 124-share transaction.

The shares most recently traded at $18.24, up $0.16, or 0.88% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares bought: 9,100
  • 4-Week # shares sold: 701
  • 12-Week # shares bought: 9,100
  • 12-Week # shares sold: 701
  • 24-Week # shares bought: 9,100
  • 24-Week # shares sold: 3,700

The average volume for Foundation Medicine has been 261,600 shares per day over the past 30 days. Foundation Medicine has a market cap of $639.7 million and is part of the health care sector and health services industry. Shares are down 16.76% year-to-date as of the close of trading on Tuesday.

Foundation Medicine, Inc. provides various molecular information products in the United States. Currently, there is 1 analyst who rates Foundation Medicine a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings

rates Foundation Medicine as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

Foundation Medicine Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DexCom (DXCM) - FREE Research Report

Pacelli Steven Robert, who is EVP, Strategy & Corp. Dev. at DexCom, sold 20,600 shares at $70.62 on April 5, 2016. Following this transaction, the EVP, Strategy & Corp. Dev. owned 204,118 shares meaning that the stake was reduced by 9.17% with the 20,600-share transaction.

The shares most recently traded at $68.30, down $2.32, or 3.4% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 7,030
  • 12-Week # shares sold: 32,890
  • 24-Week # shares sold: 69,355

The average volume for DexCom has been 1.0 million shares per day over the past 30 days. DexCom has a market cap of $5.8 billion and is part of the health care sector and health services industry. Shares are down 17.2% year-to-date as of the close of trading on Tuesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. Currently, there are 11 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings

rates DexCom as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

DexCom Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.